ClinicalTrials.gg
CompletedNCT01253902Updated Nov 7, 2012Results posted

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

A Phase 4 interventional study of bimatoprost ophthalmic solution 0.01% and travoprost ophthalmic solution 0.004% in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-07.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
18th of 45
164 · median 135
Started
2010
with 2 others
Phase 4
22 of 46
2 open now
Registered
25th of 46
by date
Lead sponsor
2 of 46
Allergan

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 18th largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2010, is one of 22 in phase 4, and was the 25th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®) in patients previously treated with Xalatan® who have open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ocular hypertension or open-angle glaucoma in at least 1 eye requiring treatment with an anti-glaucoma/ocular hypertensive medication
  • Best corrected visual acuity score of 20/100 or better in both eyes
  • Females on pills must be on same type of pill and dose for at least 3 month

Exclusion criteria

Exclusion Criteria:

  • Use of Lumigan® 0.01%/Lumigan® RC, Lumigan®, Travatan® or Travatan Z® within 6 months
  • History of or active ocular infection/inflammation (eg, uveitis)
  • Punctal plug use
  • Required use of ocular medications during the study other than study medication (intermittent use of certain types artificial tears acceptable)
  • Intraocular surgery or glaucoma laser surgery in study eye(s) within 3 months
  • History of corneal refractive laser surgery (eg, LASIK, LASEK) in study eye(s)
  • Planned contact lens wear during study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
164 participants (actual)

Study arms

  • Active comparator
    bimatoprost ophthalmic solution 0.01%

    One drop of bimatoprost ophthalmic solution 0.01% (Lumigan®) administered to affected eye(s), once daily in the evening for 12 weeks.

    Drug: bimatoprost ophthalmic solution 0.01%

  • Active comparator
    travoprost ophthalmic solution 0.004%

    One drop of travoprost ophthalmic solution 0.004% (Travatan Z®) administered to affected eye(s), once daily in the evening for 12 weeks.

    Drug: travoprost ophthalmic solution 0.004%

  • Active comparator
    latanoprost ophthalmic solution 0.005%

    One drop of latanoprost ophthalmic solution 0.005% (Xalatan®) administered to affected eye(s), once daily in the evening for 12 weeks.

    Drug: latanoprost ophthalmic solution 0.005%

Interventions

  • One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.

    Also known as: Lumigan® 0.01%, Lumigan® RC

  • One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.

    Also known as: Travatan Z®

  • One drop of latanoprost ophthalmic solution 0.005% administered to affected eye(s), once daily in the evening for 12 weeks.

    Also known as: Xalatan®

06

What researchers measure

Primary outcomes

  1. Mean Conjunctival Hyperemia at Week 12

    Conjunctival hyperemia was analyzed using the average of the scores of both eyes. Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia was graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness).

    Time frame: Week 12

Secondary outcomes

  1. Mean Corneal Staining With Fluorescein at Week 12

    Corneal staining was analyzed using the average of the scores of both eyes. The cornea is the transparent front part of the eye which covers the iris and pupil. To detect the presence or absence of corneal puncta (tiny disruptions in the surface of the eye), fluorescein dye is administered into the eye and the eye is graded using a 5-point scale where 0=None (no puncta), 0.5=Trace (1-5 puncta), 1=Mild (6-20 puncta), 2=Moderate (\>20 puncta) and 3=Severe (too many puncta to count).

    Time frame: Week 12

  2. Mean Tear Break Up Time (TBUT) at Week 12

    Tear Break Up Time was analyzed using the average of the readings of both eyes. TBUT is defined as the time (seconds) required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film.

    Time frame: Week 12

07

Results

Posted Nov 7, 2012

Participant flow

Participant flow — Overall Study
MilestoneBimatoprost Ophthalmic Solution 0.01%Travoprost Ophthalmic Solution 0.004%Latanoprost Ophthalmic Solution 0.005%
Started565355
Completed515151
Not completed524

Outcome measures

PrimaryMean Conjunctival Hyperemia at Week 12

Conjunctival hyperemia was analyzed using the average of the scores of both eyes. Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia was graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness).

Time frame:
Week 12
Reported as:
Mean · Score on a scale
Mean Conjunctival Hyperemia at Week 12
Score on a scaleBimatoprost Ophthalmic Solution 0.01%Travoprost Ophthalmic Solution 0.004%Latanoprost Ophthalmic Solution 0.005%
Mean Conjunctival Hyperemia at Week 120.42 ± 0.480.46 ± 0.440.44 ± 0.57
SecondaryMean Corneal Staining With Fluorescein at Week 12

Corneal staining was analyzed using the average of the scores of both eyes. The cornea is the transparent front part of the eye which covers the iris and pupil. To detect the presence or absence of corneal puncta (tiny disruptions in the surface of the eye), fluorescein dye is administered into the eye and the eye is graded using a 5-point scale where 0=None (no puncta), 0.5=Trace (1-5 puncta), 1=Mild (6-20 puncta), 2=Moderate (\>20 puncta) and 3=Severe (too many puncta to count).

Time frame:
Week 12
Reported as:
Mean · Score on a scale
Mean Corneal Staining With Fluorescein at Week 12
Score on a scaleBimatoprost Ophthalmic Solution 0.01%Travoprost Ophthalmic Solution 0.004%Latanoprost Ophthalmic Solution 0.005%
Mean Corneal Staining With Fluorescein at Week 120.31 ± 0.450.32 ± 0.480.22 ± 0.30
SecondaryMean Tear Break Up Time (TBUT) at Week 12

Tear Break Up Time was analyzed using the average of the readings of both eyes. TBUT is defined as the time (seconds) required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film.

Time frame:
Week 12
Reported as:
Mean · Seconds
Mean Tear Break Up Time (TBUT) at Week 12
SecondsBimatoprost Ophthalmic Solution 0.01%Travoprost Ophthalmic Solution 0.004%Latanoprost Ophthalmic Solution 0.005%
Mean Tear Break Up Time (TBUT) at Week 129.7 ± 5.719.7 ± 4.969.3 ± 4.04

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bimatoprost Ophthalmic Solution 0.01%—1/56 (1.8%)0/56 (0%)
Travoprost Ophthalmic Solution 0.004%—1/53 (1.9%)0/53 (0%)
Latanoprost Ophthalmic Solution 0.005%—3/55 (5.5%)0/55 (0%)
Most frequent serious events
Most frequent serious events
EventBimatoprost Ophthalmic Solution 0.01%Travoprost Ophthalmic Solution 0.004%Latanoprost Ophthalmic Solution 0.005%
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/561/530/55
Gastrointestinal BleedGastrointestinal disorders0/560/531/55
Aspiration Pneumonia resulting in deathRespiratory, thoracic and mediastinal disorders0/560/531/55
Punctured colonGastrointestinal disorders0/560/531/55
Infection from Punctured colonInfections and infestations0/560/531/55
Transient Ischemic AttackVascular disorders0/560/531/55
Branch retinal artery occlusionEye disorders1/560/530/55

Baseline characteristics

Age Continuous
Age Continuous(Years)Bimatoprost Ophthalmic Solution 0.01%Travoprost Ophthalmic Solution 0.004%Latanoprost Ophthalmic Solution 0.005%Total
Mean65.1 ± 11.7663.2 ± 13.5764.7 ± 12.2864.3 ± 12.49
Sex: Female, Male
Sex: Female, Male(Participants)Bimatoprost Ophthalmic Solution 0.01%Travoprost Ophthalmic Solution 0.004%Latanoprost Ophthalmic Solution 0.005%Total
Female36253192
Male20282472
08

Study locations

2 sites
  • Rogers, Arkansas, United States
  • Calgary, Alberta, Canada
09

References and documents

Publications

  • Schwartz GF, Hollander DA, Williams JM. Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension. Curr Med Res Opin. 2013 Nov;29(11):1515-22. doi: 10.1185/03007995.2013.833898. Epub 2013 Sep 5. PubMed 24006861 ↗
  • Crichton AC, Vold S, Williams JM, Hollander DA. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension. Adv Ther. 2013 Mar;30(3):260-70. doi: 10.1007/s12325-013-0014-7. Epub 2013 Mar 7. PubMed 23475405 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2010
First posted
Dec 6, 2010
Start
Dec 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Nov 7, 2012
Last update
Nov 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01253902
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Dec 6, 2010
Start date
Dec 2010
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Nov 7, 2012
Last update
Nov 7, 2012

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bimatoprost Ophthalmic Solution · Travoprost · Latanoprost

Start the discussion